Categories
Cosmic Science

When pandemics mix with politics, it’s unhealthy

For years, public health officials at the Centers for Disease Control and Prevention have been playing out scenarios for dealing with pandemics, but the one scenario they didn’t count on was that they’d be hamstrung by their own political leaders.

“I don’t think anybody ever thought that that would happen,” said Maryn McKenna, a veteran reporter on infectious diseases. “And yet, seven months into the pandemic here in the United States, that’s pretty much where we are.”

McKenna and others involved in the response to the coronavirus outbreak discussed the role that politics has played in the pandemic, during a presentation organized by the National Association of Science Writers and the Council for the Advancement of Science Writing.

Today’s session served as the kickoff for a free weekly series of online events focusing on COVID-19, offered for journalists as well as the public in conjunction with the annual ScienceWriters conference.

Panelists agreed that mixed messages from the nation’s leaders have hampered efforts to combat the pandemic, which has claimed the lives of more than 200,000 Americans. Just today, Cornell University researchers said their analysis pointed to President Donald Trump as “the single largest driver of misinformation around COVID.”

Such misinformation has taken the form of conspiracy theories about the origins and spread of the coronavirus that causes COVID-19, plus the hype surrounding supposed “miracle” cures and efforts to downplay the seriousness of the outbreak.

Marsha Jones — co-founder and executive director of The Afiya Center, a Texas-based reproductive justice organization — said she’s seen it all before, during the AIDS crisis of the 1980s and 1990s.

“I didn’t think that I would ever see a disease so politicized as HIV was ever again, because for some reason I thought we learned,” she said.

Like the HIV epidemic, the COVID-19 epidemic is dealing a particularly heavy blow to people “who get the least amount of funding, who get the least amount of recognition, who have the worst care,” Jones said.

And even as the outbreak is raging, disadvantaged communities are struggling with the repercussions of systemic racism and urban unrest. “We’re living in a dual epidemic,” Jones said.

Science is suffering along with society, said Peter Daszak, president of the New York-based EcoHealth Alliance. His group became the focus of controversy early in the pandemic because it helped train Chinese virologists in Wuhan, which was the outbreak’s global epicenter.

The training effort was part of a federally funded program called PREDICT, which aimed to anticipate cross-species viral outbreaks. The Trump administration let the program expire last year, just before the first COVID-19 cases came to light — and EcoHealth Alliance faced heavy criticism largely because of unfounded accusations that the virus was unleashed from the Wuhan virology lab.

“It’s the right wing, it’s QAnon, it’s people spending hours in their basements doing ‘research’ on the internet to dig up stuff that sounds like a conspiracy,” Daszak said. “And of course, with so much online presence, the president not only allows that to happen, but also promotes it, and seems to believe it himself.”

Scientists tend to be uncomfortable about getting into the political fray, but Daszak said inaction may no longer be an option. “During the HIV pandemic, science got political, and scientists got political,” he said. “It’s no good keeping quiet. You’ve got to push back, and push back strong, and tell the truth about what’s going on. … If you keep quiet, you’ve just basically consigned science to the trash heap.”

So what is to be done? The panelists said the political outlook could brighten next year. There’s already an effort in the works to get a virus surveillance program called Stop Spillover funded, and Democratic presidential candidate Joe Biden has promised to revive PREDICT.

McKenna said Biden could also reverse cutbacks in public health spending and shore up the CDC’s data-gathering operation.

But politicians aren’t the only ones who can play a role in repairing public policy on pandemics, Daszak said.

“You’re journalists,” he told the online audience. “So get out there and speak the truth, and push back.”

McKenna said it’s crucial for all journalists to be trained to cover the different facets of coronavirus coverage, ranging from biology to business, from epidemiology to education.

“We should rethink the silos within which we exist as journalists … because it’s entirely possible that a science and public health story like the coronavirus pandemic will come in and cut across all those silos, and demonstrate the degree to which we have not trained each other in the mutual knowledge that we all need,” she said.

Daszak said truth-telling shouldn’t be confined to a newsroom setting.

“Go talk to your neighbors and friends,” he said. “And also, you know, the folks with the Trump sign outside their house. Go have a chat with them, see what they think about masks and school openings. Listen to them, and say a couple of things, a couple of facts, nothing heavy, and just let it settle and move away. … We need a societal change in our understanding of things like this pandemic.”

Jones stressed that you don’t need to be a politician — or a journalist, or a public health worker, for that matter — to parry the pandemic.

“The greatest changes don’t necessarily have to happen in the political arena. “There are changes that can happen outside of that, that will inevitably impact what’s happening in the political arena,” she said.

She advised starting with the place where you have the most influence, even if it’s outside the traditional halls of power.

“If that’s at your house, if that’s on your porch, in the park, in the gym — wherever it is that you have the most power, and you can have the most convincing conversation where you’re talking with somebody who can create change, that’s what you do,” Jones said.

From the CDC: How to protect yourself and others

I’ll update this report with the archived video from today’s #SciWriCOVID presentation once it’s available. The next presentation in the “COVID-19 Science and Coverage” series is scheduled for Oct. 7, starting at 5 p.m. ET (2 p.m. PT). The theme is “Reporting on the Pandemic.” Panelists include STAT senior writer Helen Branswell; Laura Helmuth, editor in chief of Scientific American; Patrice Peck, creator of the newsletter Coronavirus News for Black Folks; and Zeynep Tufekci, a contributing writer at The Atlantic

Full disclosure: I’m the president of the Council for the Advancement of Science Writing, which is one of the organizers of the series. FiveThirtyEight senior science writer Maggie Koerth, a CASW board member, moderated today’s session. 

Categories
Cosmic Science

Antibody cocktail just might ward off COVID-19

An international research team led by University of Washington scientists has identified two kinds of “ultrapotent human antibodies” that could go into a drug cocktail for guarding against COVID-19.

  • UW’s David Veesler and Vir Biotechnology’s Katja Fink are the senior authors of the study published online today by the journal Science, which highlights two monoclonal antibodies known as S2E12 and S2M11. The antibodies were found to block SARS-CoV-2, the coronavirus that causes COVID-19, from latching onto molecular receptors on cells in hamsters.
  • An analysis of the antibodies’ molecular structure determined that they block the virus by gumming up its characteristic “spike” protein, which has been a target for many of the vaccines and therapies under development to fight COVID-19. Some of the researchers behind the newly published study, including Veesler, reported a similarly promising antibody called S309 in May.
  • Researchers say such antibodies could be combined in a drug cocktail to guard against the virus evolving to evade any single one of the ingredients. A drug that takes advantage of S309’s effect is already being tested in a phase 2/3 clinical trial launched by GlaxoSmithKline and Vir Biotechnology.

The principal authors of the Science study, “Ultrapotent Human Antibodies Protect Against SARS-CoV-2 Challenge Via Multiple Mechanisms,” are M. Alejandra Tortorici of the University of Washington and Martina Beltramello of France’s Pasteur Institute and CNRS. Other UW researchers among the 47 co-authors of the study include Ha Dang, Matthew McCallum and John Bowen.

This report was first published on GeekWire.

Categories
GeekWire

Genetic sleuths flesh out pandemic’s origin story

Detailed genetic analyses of the strains of virus that cause COVID-19 suggest that the outbreak took hold in Washington state in late January or early February, but went undetected for weeks.

That’s the upshot of two studies published by the journal Science, based on separate efforts to trace the genetic fingerprints of the coronavirus known as SARS-CoV-2.

The studies draw upon analyses of more than 10,000 samples collected in the Puget Sound region as part of the Seattle Flu Study during the early weeks of the outbreak, plus thousands more samples from other areas of the world.

One of the studies was conducted by a team including Trevor Bedford, a biologist at Seattle’s Fred Hutchinson Cancer Research Center who has been issuing assessments of the virus and its spread since the earliest days of the outbreak. The first version of the team’s paper went online back in March and was revised in May, months in advance of today’s peer-reviewed publication.

The other study comes from researchers led by the University of Arizona’s Michael Worobey, who also published a preliminary version of their results in May.

Get the full story on GeekWire.

Categories
GeekWire

Scientists design proteins that confound coronavirus

Imagine being able to ward off COVID-19 just by spritzing a nasal spray into your nostrils. It may not be just your imagination: Researchers at the University of Washington have designed a batch of synthetic proteins that could conceivably block the coronavirus behind this year’s pandemic from gaining a foothold.

“Although extensive clinical testing is still needed, we believe the best of these computer-generated antivirals are quite promising,” Longxing Cao, a postdoctoral scholar at UW’s Institute for Protein Design, said in a news release.

Cao is the lead author of a study about the protein-building experiment, published today by the journal Science. It’s the latest innovation to come from the emerging field of protein engineering, and the technique could revolutionize how drugs are developed to counter future pandemics.

It may not be too late to counter COVID-19 as well. “We are working to get improved versions … deployed to fight the current pandemic,” senior study author David Baker, the director of the Institute for Protein Design, told GeekWire in an email.

The technique involves creating small-molecule proteins, or mini-binders, that are custom-designed to latch onto the spiky molecular structures that are scattered around the surface of SARS-CoV-2, the virus that causes COVID-19.

The spikes on the virus do their dirty work by fitting into molecular-scale receptors on the surfaces of cells, much like fitting a key into a lock to gain entry to someone’s house. Once the virus “unlocks” a receptor, it gains entry to the cell, hijacks its chemical machinery and churns out more virus particles to spread the infection.

Baker, Cao and their colleagues used high-powered computers to design more than 2 million candidate proteins that could conceivably gum up the works for the virus’ spike protein. More than 118,000 of the most promising candidates were synthesized and tested on lab-grown cells.

Get the full story on GeekWire.

Categories
GeekWire

‘Three Little Pigs’ demonstrate Neuralink’s brain implant

With grudging assistance from a trio of pigs, Neuralink co-founder Elon Musk showed off the startup’s state-of-the-art neuron-reading brain implant and announced that the system has received the Food and Drug Administration’s preliminary blessing as an experimental medical device.

During today’s demonstration at Neuralink’s headquarters in Fremont, Calif., it took a few minutes for wranglers to get the swine into their proper positions for what Musk called his “Three Little Pigs demonstration.”

One of the pigs was in her natural state, and roamed unremarkably around her straw-covered pen. Musk said the second pig had been given a brain implant that was later removed, showing that the operation could be reversed safely.

After some difficulty, a third pig named Gertrude was brought into her pen. As she rooted around in the straw, a sequence of jazzy electronic beeps played through the sound system. Musk said the tones were sounded whenever nerves in the pig’s snout triggered electrical impulses that were picked up by her brain implant.

“The beeps you’re hearing are real-time signals from the Neuralink in Gertrude’s head,” he said.

Eventually, Neuralink’s team plans to place the implants in people, initially to see if those who have become paralyzed due to spinal cord injuries can regain motor functions through thought alone.

Musk said the implant received a Breakthrough Device designation from the FDA last month. That doesn’t yet clear the way for human clinical trials, but it does put Neuralink on the fast track for consultation with the FDA’s experts during preparations for such trials.

Neuralink has received more than $150 million in funding, with roughly two-thirds of that support coming from Musk himself. Today he said the venture had about 100 employees. He expects that number to grow. “Over time, there might be 10,000 or more people at Neuralink,” he said.

Get the full story on GeekWire.

Categories
GeekWire

A new way to fight COVID-19 and other viral threats

A team including researchers from Seattle’s Benaroya Research Institute at Virginia Mason has identified a new pathway for protecting cells from deadly viruses — including the coronavirus that causes COVID-19 as well as the Ebola virus.

The technique, described in this week’s issue of the journal Science, takes advantage of a screening technique for seeking out new genes that can prevent infection.

In the newly published study, the research team pinpoints two genes that have already been the subject of biomedical studies. One gene is called the MHC class II transactivator, or CIITA. The second gene is known as CD74 — specifically, a variant known as p41.

Those genes have previously been thought to be involved in conventional immune responses involving T cells and B cells. The new findings, resulting from a screening technique called transposon-mediated gene activation, shed light on a different way in which the genes block infection.

The researchers found that CIITA can induce resistance in human cell lines by activating CD74 p41, which in turn disrupts the processing of proteins on the coat of the Ebola virus protein. That stops the virus from being able to infect its target cell. The same process blocks the entry pathway for an assortment of coronaviruses — including the SARS-CoV-2 virus that’s behind the current pandemic.

Get the full story on GeekWire.

Categories
GeekWire

Synthetic proteins use logic to choose which cells to kill

The age of molecular-scale computing is entering a new era, thanks to the development of a system that uses synthetic proteins and Boolean logic to identify cancer cells.

The proteins can lock onto chemical markers on the surface of cells in predetermined combinations, performing the roles of logical AND, OR and NOT gates. It’s similar to the way binary computers do their thing, but with biochemistry rather than electronic bits.

“We were trying to solve a key problem in medicine, which is how to target specific cells in a complex environment,” Marc Lajoie, one of the lead authors of a study published today in the journal Science, explained in a news release.

“Unfortunately, most cells lack a single surface marker that is unique to just them. So, to improve cell targeting, we created a way to direct almost any biological function to any cell by going after combinations of cell surface markers,” Lajoie said.

Lajoie worked on the effort during his stint as a postdoctoral scholar at the University of Washington’s Institute for Protein Design. He’s now co-director for protein and cell engineering at Lyell Immunopharma, a California-based startup aiming to commercialize the technique.

Get the full story on GeekWire.

Categories
Cosmic Science

XPRIZE organizes $5M challenge for COVID-19 tests

The nonprofit XPRIZE foundation has assembled a high-powered coalition to take on a high-priority problem: developing high-quality screening tests for COVID-19 that are low-cost and easy to use with a fast turnaround time.

The $5 million XPRIZE Rapid Covid Testing competition is the latest project from the folks who created multimillion-dollar contests for privately financed spaceships, super-efficient cars and real-life equivalents of Star Trek’s medical tricorders.

Among those voicing support for the testing development effort are:

  • OpenCovidScreen, a nonprofit group that numbers researchers from such institutions as the University of Washington and business leaders from such companies as Illumina among its advisers and collaborators. OpenCovidScreen’s partners include ThermoFisher Scientific, Google, Amazon and Ancestry.com. The group’s president and co-founder is Jeff Huber, a former Google executive and co-founder of Grail, a cancer detection startup.
  • A $50 million fund known as the COVID Apollo Project, backed by investors including RA Capital, Bain Capital, Perceptive Advisors, Redmile Group and Samsara Biocapital.
  • Healthcare companies including Anthem, Blue Shield of California, BlueCross / BlueShield of South Carolina and Cambia Health Solutions.
  • California Gov. Gavin Newsom, who said in a statement that he looks forward to “seeing the breakthroughs that arise from this challenge and the countless lives that will be saved as a result.”

Teams can compete in one of four categories, focusing on at-home tests, point-of-care tests, distributed lab tests or high-throughput lab tests. They’ll be asked to develop new tests that produce results within 12 hours of collecting a sample, using minimally invasive procedures.

Winning teams will be required to deploy and conduct a minimum of 500 tests per week at a live testing site within 60 days, and have the potential to scale up their solutions to thousands of tests per week.

Cost of the test should be less than $15, including all materials, with avenues for reducing costs as production is scaled up.

Currently, the cost of COVID-19 testing can range from less than $100 to more than $1,000, depending on healthcare circumstances. What’s more, the turnaround time for test results can extend past a week, due to shortages in supplies and staffing.

“Fast, affordable, and accessible testing is crucial to containing the COVID-19 pandemic and safely reopening schools, businesses and other vital institutions around the world,” XPRIZE CEO Anousheh Ansari said. “XPRIZE Rapid Covid Testing is inspiring the best entrepreneurial and scientific teams to come together to work towards rapid, affordable Covid-19 testing at scale, and ultimately, getting the world up and running again.”

Teams must register by Aug. 31, and the XPRIZE timeline calls for tests to be deployed in a pilot round that runs from Nov. 2, 2020, to Jan. 22, 2021. Winners are to be announced by the end of next January, with scaled-up production planned during the months that follow.

The reaction to today’s announcement was mostly positive. “THIS is what we need right now,” Eric Feigl-Ding, an epidemiologist at the Federation of American Scientists, said in a tweet.

However, the Food and Drug Administration is likely to have the final word on any tests that come out of the competition. And even without the contest, progress is being made on rapid-turnaround COVID-19 tests. There’s a chance that this XPRIZE will be rendered unnecessary before it reaches its climax. It wouldn’t be the first time.

Categories
GeekWire

NASA funds 400 bright ideas from small businesses

NASA says it’ll fund more than 400 ideas from small businesses, aimed at creating technologies ranging from plumbing fixtures suitable for the moon to AI-based medical assistants that can provide “an extra pair of trained eyes” for crews on Mars.

The contracts will provide about $51 million to 312 small businesses in 44 states and Washington, D.C., to support the development of technologies that could come in handy for space exploration or Earth-based applications.

Get the full story on GeekWire.

Categories
GeekWire

Elon Musk’s COVID-19 tweets get a reality check

Billionaire Elon Musk knows his stuff when it comes to rockets or electric cars. But does that translate into epidemiological expertise? Not completely, according to Washington state’s coronavirus trackers.

Musk weighed in today with a Twitter response to a GeekWire story that focused on Washington’s rising number of COVID-19 cases as well as Washington Gov. Jay Inslee’s appearance on CBS’ “Face the Nation.”

Get the full story on GeekWire.